BBIO Q2 2025 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$111M+4999.9% YoY

Gross Profit

$107M96.7% margin

Operating Income

-$134M-121.4% margin

Net Income

-$182M-164.5% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

-5.2%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$86M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$2.9B

Stockholders' Equity

-$1.8B

Cash & Equivalents

$749M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$111M	$2M	+4999.9%
Gross Profit	$107M	$2M	+6709.7%
Operating Income	-$134M	-$176M	+23.5%
Net Income	-$182M	-$73M	-147.6%

Revenue Segments

Net Product Revenue

$72M98%

Royalty Revenue

$2M2%